What DiffBiome FMT is, and how it restores balance

You will understand what is in your capsule and how it works: the living, diverse gut flora of a healthy donor, which engrafts in your gut, restores balance, and pushes back C. difficile.

What is FMT, and what is in your capsule?

FMT^[G] — that is, faecal microbiota transplantation^[G] — rests on a simple core idea: if the infection and the antibiotics have emptied out your protective gut flora, then we replace it with the whole, diverse flora of a healthy person. We do not give a single bacterial strain, as conventional probiotics do, but an entire, functioning community — exactly what is needed to restore dysbiosis^[G].

In the case of DiffBiome, this happens not through an uncomfortable procedure but through a simple capsule^[G]. The capsule contains gut flora from a healthy, thoroughly screened and verified donor^[G], in dried form. The drying (the technical term for it is lyophilisation) allows the living bacteria to be kept viable and stable, refrigerated, for a long time, and to be concentrated into a small capsule that can be taken painlessly, even at home.

This is an enormous advantage over the earlier, more uncomfortable methods: there is no need for a colonoscopy or an enema. The capsule form is convenient, can be used at home as an outpatient, and makes it easier to stick to the course. The contents of your capsule are therefore not a medicine in the usual sense, but life itself — the whole, functioning ecosystem of a healthy gut.

How does it restore balance?

When you take the capsule, the living bacteria inside reach your gut and begin to settle in — this process is what we call engraftment^[G]. The diverse community delivered occupies the places that were emptied out by dysbiosis, and repopulates your gut with the rich flora that became depleted because of the infection and the antibiotics.

As this community engrafts, the natural protection — colonisation resistance^[G] — gradually returns: the restored flora^[G] takes up the space and the nutrients away from C. difficile, and creates an environment in which the pathogen's spores cannot germinate and multiply. The overgrowth of C. difficile recedes, toxin production falls, and your symptoms ease too.

This explains why this approach is more effective in recurrent infection than continuous courses of antibiotics: it does not merely attack the pathogen, but restores the fundamental balance whose absence was feeding the relapses. In your diary, over the coming days and weeks, you can follow for yourself how your symptom trend turns in the right direction in step with engraftment. Patience matters here: engraftment is a process, not a moment — but the process is working for you.

What to expect during engraftment

In the first days, engraftment may sometimes come with mild, transient discomfort: bloating, gassiness and abdominal discomfort can occur. This is mostly normal — a by-product of the gut flora rearranging itself — and usually eases on its own. Even so, continue the course as agreed, and watch in your diary how the complaints develop.

What is not normal is any of the red flags: severe, cramping abdominal pain, high fever, fresh blood in the stool, signs of dehydration. These always require urgent medical evaluation. The difference between transient, mild bloating and warning signs is precisely why daily diary-keeping and the conscious observation of symptoms are so useful — they help you too to judge what belongs to the course of recovery, and when you need to raise the alarm.

🍽️ Eating during these days

In these three days you come to understand what is in your capsule and how the new flora engrafts — and your diet supports this engraftment, still on the gentle, firming line. Your tasks are simple: take the daily dose according to the usual routine, drink an extra glass of water after every looser stool, and do not start a probiotic or antibiotic course on your own that would disturb the freshly arrived flora.

For these days, the Plant Calendar recommends sources high in pectin that are traditionally stool-firming: on day 16 quince (stewed or as a compote), on day 17 grated or stewed apple, and on day 18 blueberries (which contain tannin in addition to pectin). Pectin is a soluble fibre: it forms a gel in water, slows the passage of the gut contents, and so supports a firmer stool while your symptoms settle. Build the plant of the day into at least one meal, prepared gently; if you do not tolerate one of them, leave it out and return to it later.

References

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[36] Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017. Link

European consensus conference developing evidence-based recommendations on FMT for clinical practice, with 28 experts from 10 countries collaborating in working groups. Statements were generated through evidence-based review, evaluated electronically via a Delphi process, and finalized in a plenary consensus session. Recommendations cover FMT indications, donor selection, faecal material preparation, clinical management, faecal delivery, and minimum requirements for establishing an FMT centre. Provides the European standardization framework for safe and governed FMT delivery.

[349] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021. Link

This 2021 IDSA/SHEA focused-update guideline addresses fidaxomicin and bezlotoxumab in adult C. difficile infection (CDI) management. Recommendations were derived from systematic literature review and graded using GRADE. The panel recommends fidaxomicin over vancomycin for initial CDI episode and for first recurrence (conditional, moderate certainty), citing reduced recurrence risk. Bezlotoxumab is suggested as adjunct to standard antibiotic therapy for patients at high risk of CDI recurrence (conditional, very low certainty). The update reflects accumulating RCT evidence and refines positioning of newer agents within the CDI treatment algorithm.

[365] Reed AD, Theriot CM. Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium. Microorganisms. 2021. Link

This review examines how commensal Clostridium species mediate colonization resistance against C. difficile. Commensal Clostridia modify primary bile acids into secondary bile acids that suppress C. difficile spore germination and vegetative outgrowth. They additionally produce antimicrobial peptides and short-chain fatty acids that directly inhibit C. difficile and compete for limiting nutrients such as proline, important for C. difficile growth via Stickland fermentation. Loss of commensal Clostridia after broad-spectrum antibiotics is a key mechanistic step toward CDI susceptibility. The authors argue that restoring defined Clostridium consortia is a rational, mechanism-driven alternative to FMT for preventing recurrent CDI.

[369] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015. Link

This study tracked fecal microbiota dynamics in four patients with multiply recurrent, antibiotic-refractory C. difficile infection treated with FMT, sampling daily up to 28 days and weekly up to 84 days post-FMT (with sampling out to 151 days). 16S rRNA gene profiling was compared to Human Microbiome Project body-site references. Pre-FMT samples were markedly dysbiotic. FMT produced a rapid normalization of fecal community composition toward a healthy donor-like state within days, and this normalization was largely sustained over months. Time-course visualization highlighted both rapid early shifts and longer-term stabilization. The findings document the kinetics of FMT-driven microbiota recovery in refractory CDI and support its durability.